Brokerages Set Zura Bio Limited (NASDAQ:ZURA) Price Target at $14.00

Shares of Zura Bio Limited (NASDAQ:ZURA) have been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $17.00.

A number of equities research analysts have recently weighed in on ZURA shares. Guggenheim lifted their price target on Zura Bio from $15.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. William Blair initiated coverage on Zura Bio in a research note on Wednesday, July 8th. They set an “outperform” rating on the stock. Wedbush boosted their price target on Zura Bio from $15.00 to $22.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a report on Monday, July 6th. Finally, Wall Street Zen upgraded shares of Zura Bio from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st.

Institutional Investors Weigh In On Zura Bio

A number of institutional investors have recently bought and sold shares of ZURA. Commodore Capital LP bought a new stake in shares of Zura Bio in the 1st quarter valued at approximately $19,338,000. Siren L.L.C. lifted its stake in Zura Bio by 187.3% in the first quarter. Siren L.L.C. now owns 3,734,866 shares of the company’s stock valued at $22,222,000 after acquiring an additional 2,434,866 shares during the last quarter. JPMorgan Chase & Co. grew its position in Zura Bio by 78.7% in the second quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock worth $4,893,000 after acquiring an additional 2,052,732 shares in the last quarter. EcoR1 Capital LLC bought a new stake in Zura Bio in the first quarter worth approximately $7,019,000. Finally, Stempoint Capital LP acquired a new position in shares of Zura Bio during the 1st quarter worth $4,483,000. 61.14% of the stock is currently owned by institutional investors and hedge funds.

Zura Bio Stock Up 1.7%

ZURA opened at $5.85 on Monday. Zura Bio has a 52-week low of $1.88 and a 52-week high of $7.44. The company has a 50 day moving average of $5.21 and a two-hundred day moving average of $5.39. The company has a market cap of $555.05 million, a P/E ratio of -5.18 and a beta of -0.02.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings results on Tuesday, June 30th. The company reported ($0.21) earnings per share for the quarter. Research analysts anticipate that Zura Bio will post -0.81 earnings per share for the current year.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.